Partial
Partially Aligned
Patient Risk:
Info
Summary
Some claims match label content (approved indications and EGFR mutation/TKI progression criterion; contraindications are 'None'), but the provided approval date and the idea of later label expansion cannot be verified from the supplied label excerpts, so alignment is only partial.
Category Scores
Accurate Statements
The November 2015 FDA approval of osimertinib was for treating patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have an activating EGFR mutation.
Indications in Section 1 include treatment of metastatic EGFR mutation-positive NSCLC (e.g., 1.5 is metastatic EGFR T790M+ after EGFR TKI; other metastatic EGFR exon 19 del/exon 21 L858R indications are also present in Section 1 excerpts). The provided excerpts support EGFR mutation-positive metastatic NSCLC as an indication, but do not link it specifically to the November 2015 approval date.
The November 2015 FDA approval of osimertinib was for patients with metastatic NSCLC with activating EGFR mutations who progressed on or after EGFR TKI therapy.
Section 1.5: 'indicated... whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.'
After initial approval, the label for osimertinib later expanded to include additional patient groups and settings.
Cannot be confirmed or refuted from the supplied label excerpts; however, the excerpts show multiple distinct indications (adjuvant, stage III unresectable, first-line metastatic, combination with pemetrexed/platinum, and post–EGFR TKI T790M+), which is consistent with label expansions over time. No explicit timeline is provided in excerpts.
Unsupported Statements
Osimertinib (Tagrisso) was approved by the U.S. Food and Drug Administration (FDA) in November 2015.
The supplied prescribing information excerpts (Sections 1, 2, 4, 5, 6, 7, 8) do not provide an approval date or approval timeline.
The November 2015 FDA approval of osimertinib was for treating patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have an activating EGFR mutation.
While the excerpts support that TAGRISSO is indicated for metastatic EGFR mutation-positive NSCLC in current labeling, they do not specify what the label indicated at the time of the November 2015 approval.
The November 2015 FDA approval of osimertinib was for patients with metastatic NSCLC with activating EGFR mutations who progressed on or after EGFR TKI therapy.
The excerpts support the 'progressed on or after EGFR TKI therapy' criterion for a current indication (Section 1.5), but they do not confirm that this was the specific scope of the November 2015 approval.
Contradictions
Important Omissions
No AI response was provided describing the requested label alignment beyond the four claims; specifically, there is no assessment of dosage, boxed warnings, or contraindications in the provided claims (e.g., 'None' in contraindications, ILD/pneumonitis, QTc prolongation).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The claims primarily concern approval date and indication scope rather than dosing or safety instructions. Two claims about indication criteria are directionally supported by the label excerpts but cannot be tied to the November 2015 approval date from the provided text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Approval date and its specific scope cannot be verified from the supplied prescribing information excerpts.
Suggested Improvement
Remove or qualify the November 2015 approval-date claims unless the provided label text includes the approval date and describes the exact indication at approval. Limit indication statements to what the current label excerpts specify without attributing them to the approval date.